NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

909.90 -12.00 (-1.30%)

30.22% Fall from 52W High

167.6K NSE+BSE Volume

NSE 26 Sep, 2025 3:31 PM (IST)

17,885.3

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

US FDA Approval

Alembic Pharma gets US FDA nod for its ANDA for Paroxetine tablets, with a $1.2 billion market size See details

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

12 Aug 2025

909.90

-1.30%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

06 Aug 2025

909.90

-1.30%

Turnaround in US growth; tepid traction in India

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

05 Aug 2025

909.90

-1.30%

Export strength offsets muted DF/API show

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a largely in-line performance for 1QFY26. Superior execution in the export market led to YoY growth in revenue/EBITDA/PAT for the quarter.

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

07 May 2025

909.90

-1.30%

Alembic Pharma (BUY): FY26 to be better than FY25

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

06 May 2025

909.90

-1.30%

Exports outshine; API witnesses gradual recovery

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a better-than-expected performance in 4QFY25. A strong performance in export markets was offset partly by a muted show in domestic formulation (DF) segment.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

12 Feb 2025

909.90

-1.30%

Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

04 Feb 2025

909.90

-1.30%

In pursuit of a turnaround

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q3FY25 result was dragged by tepid performance in India and API biz. India biz growth has been weaker (5.8% in 9MFY25) for the last couple of quarters due to pressure in acute segment even though animal health biz has been growing <20%.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

03 Feb 2025

909.90

-1.30%

Muted India business and lower operating leverage drag earnings

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered operationally in-line 3QFY25 performance. Higher interest outgo and tax led to lower-than-expected earnings for the quarter.